• Explore /
  • Poster
  • / A phase 1/2 study of DCC‑3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.

A phase 1/2 study of DCC‑3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.

Abstract Poster

Authors

null

Anthony W. Tolcher

Texas Oncology-San Antonio Babcock NEXT Oncology, San Antonio, TX

Anthony W. Tolcher , David S. Hong , Andrae Lavon Vandross , Charles M Psoinos , Denise Marie Brennan , Matthew L. Sherman , Rodrigo Ruiz-Soto , Frederic J. Reu , Colin D. Weekes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04892017

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3178)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3178

Abstract #

TPS3178

Poster Bd #

156a

Abstract Disclosures

Similar Posters

First Author: Eelke Gort

First Author: Meredith McKean

First Author: Timothy A. Yap

First Author: Manish R. Patel